An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice

Virology

Volumn 350, Issue 1, 2006, Pages 103-115

  Nakayama, Masaharu ^a   Both, Gerald W ^c   Banizs, Boglarka ^a   Tsuruta, Yuko ^a   Yamamoto, Seiji ^a   Kawakami, Yosuke ^a   Douglas, Joanne T ^a,b   Tani, Kenzaburo ^d   Curiel, David T ^a,b   Glasgow, Joel N ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c CSIRO   (Australia)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Adenovirus; Coxsackie and adenovirus receptor (CAR); Gene therapy; Kidney tropism; Liver tropism; Targeting; Tropism modification

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATADENOVIRUS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FIBER; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; KIDNEY; KIDNEY DISEASE; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STRUCTURE ANALYSIS;

ANIMALS; ATADENOVIRUS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HEART; HUMANS; KIDNEY; LIVER; LUNG; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; RECEPTORS, VIRUS; SHEEP; SPLEEN;

ADENOVIRIDAE; ATADENOVIRUS; MURINAE; OVIS;

EID: 33745028819     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.01.037     Document Type: Article

References (97)

1. Alemany R., and Curiel D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8 17 (2001) 1347-1353
2. Alemany R., Suzuki K., and Curiel D.T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81 Pt. 11 (2000) 2605-2609
3. Bai M., Harfe B., and Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J. Virol. 67 9 (1993) 5198-5205
4. Bauerschmitz G.J., Barker S.D., and Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents. (Review). Int. J. Oncol. 21 6 (2002) 1161-1174
5. Belousova N., Krendelchtchikova V., Curiel D.T., and Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J. Virol. 76 17 (2002) 8621-8631
6. Benko M., and Harrach B. A proposal for a new (third) genus within the family Adenoviridae. Arch. Virol. 143 4 (1998) 829-837
7. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 5304 (1997) 1320-1323
8. Blackwell J.L., Miller C.R., Douglas J.T., Li H., Reynolds P.N., Carroll W.R., et al. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 125 8 (1999) 856-863
9. Boyle D.B., Pye A.D., Kocherhans R., Adair B.M., Vrati S., and Both G.W. Characterisation of Australian ovine adenovirus isolates. Vet. Microbiol. 41 3 (1994) 281-291
10. Breidenbach M., Rein D.T., Wang M., Nettelbeck D.M., Hemminki A., Ulasov I., et al. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum. Gene Ther. 15 5 (2004) 509-518
11. Büchen-Osmond, C. 2002. The Universal Virus Database of the International Committee on Taxonomy of Viruses. http://www.ncbi.nlm.nih.gov/ICTVdb/index.htm.
12. Chartier C., Degryse E., Gantzer M., Dieterle A., Pavirani A., and Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70 7 (1996) 4805-4810
13. Chiu C.Y., Wu E., Brown S.L., Von Seggern D.J., Nemerow G.R., and Stewart P.L. Structural analysis of a fiber-pseudotyped adenovirus with ocular tropism suggests differential modes of cell receptor interactions. J. Virol. 75 11 (2001) 5375-5380
14. Connelly S. Adenoviral vectors for liver-directed gene therapy. Curr. Opin. Mol. Ther. 1 5 (1999) 565-572
15. Cripe T.P., Dunphy E.J., Holub A.D., Saini A., Vasi N.H., Mahller Y.Y., et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61 7 (2001) 2953-2960
16. Davison E., Diaz R.M., Hart I.R., Santis G., and Marshall J.F. Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J. Virol. 71 8 (1997) 6204-6207
17. Dmitriev I., Krasnykh V., Miller C.R., Wang M., Kashentseva E., Mikheeva G., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72 12 (1998) 9706-9713
18. Einfeld D.A., Schroeder R., Roelvink P.W., Lizonova A., King C.R., Kovesdi I., et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75 23 (2001) 11284-11291
19. Fechner H., Haack A., Wang H., Wang X., Eizema K., Pauschinger M., et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6 9 (1999) 1520-1535
20. Fujishiro J., Takeda S., Takeno Y., Takeuchi K., Ogata Y., Takahashi M., et al. Gene transfer to the rat kidney in vivo and ex vivo using an adenovirus vector: factors influencing transgene expression. Nephrol. Dial. Transplant. 20 7 (2005) 1385-1391
21. Gall J., Kass-Eisler A., Leinwand L., and Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70 4 (1996) 2116-2123
22. Gelhe W.D., and Smith K.O. Abortive infection of human cell cultures by a canine adenovirus. Proc. Soc. Exp. Biol. Med. 131 (1969) 87-93
23. Glasgow J.N., Kremer E.J., Hemminki A., Siegal G.P., Douglas J.T., and Curiel D.T. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology 324 1 (2004) 103-116
24. Goossens P.H., Havenga M.J., Pieterman E., Lemckert A.A., Breedveld F.C., Bout A., et al. Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis Rheum. 44 3 (2001) 570-577
25. Havenga M.J., Lemckert A.A., Grimbergen J.M., Vogels R., Huisman L.G., Valerio D., et al. Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol. 75 7 (2001) 3335-3342
26. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76 9 (2002) 4612-4620
27. Heikkila P., Parpala T., Lukkarinen O., Weber M., and Tryggvason K. Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system-First steps towards gene therapy of Alport syndrome. Gene Ther. 3 1 (1996) 21-27
28. Hemminki A., and Alvarez R.D. Adenoviruses in oncology: a viable option?. BioDrugs 16 2 (2002) 77-87
29. Hemminki A., Kanerva A., Kremer E.J., Bauerschmitz G.J., Smith B.F., Conductier G., et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol. Ther. 7 2 (2003) 163-173
30. Henry L.J., Xia D., Wilke M.E., Deisenhofer J., and Gerard R.D. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J. Virol. 68 8 (1994) 5239-5246
31. Hofmann C., Loser P., Cichon G., Arnold W., Both G.W., and Strauss M. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73 8 (1999) 6930-6936
32. Imai E., Takabatake Y., Mizui M., and Isaka Y. Gene therapy in renal diseases. Kidney Int. 65 5 (2004) 1551-1555
33. Jakubczak J.L., Rollence M.L., Stewart D.A., Jafari J.D., Von Seggern D.J., Nemerow G.R., et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J. Virol. 75 6 (2001) 2972-2981
34. Kanerva A., Mikheeva G.V., Krasnykh V., Coolidge C.J., Lam J.T., Mahasreshti P.J., et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8 1 (2002) 275-280
35. Khatri A., Xu Z.Z., and Both G.W. Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro. Virology 239 1 (1997) 226-237
36. Kim M., Zinn K.R., Barnett B.G., Sumerel L.A., Krasnykh V., Curiel D.T., et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur. J. Cancer 38 14 (2002) 1917-1926
37. Kim M., Sumerel L.A., Belousova N., Lyons G.R., Carcy D.E., Krasuykh V., et al. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br. J. Cancer 88 9 (2003) 1411-1416
38. Kirby T.O., Rivera A., Rein D., Wang M., Ulasov I., Breidenbach M., et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin. Cancer Res. 10 24 (2004) 8697-8703
39. Koizumi N., Mizuguchi H., Sakurai F., Yamaguchi T., Watanabe Y., and Hayakawa T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J. Virol. 77 24 (2003) 13062-13072
40. Krasnykh V.N., Mikheeva G.V., Douglas J.T., and Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70 10 (1996) 6839-6846
41. Krasnykh V., Dmitriev I., Mikheeva G., Miller C.R., Belousova N., and Curiel D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72 3 (1998) 1844-1852
42. Krasnykh V., Belousova N., Korokhov N., Mikheeva G., and Curiel D.T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol. 75 9 (2001) 4176-4183
43. Kremer E.J., Boutin S., Chillon M., and Danos O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74 1 (2000) 505-512
44. Kumin D., Hofmann C., Rudolph M., Both G.W., and Loser P. Biology of ovine adenovirus infection of nonpermissive cells. J. Virol. 76 21 (2002) 10882-10893
45. Li Y., Pong R.C., Bergelson J.M., Hall M.C., Sagalowsky A.I., Tseng C.P., et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59 2 (1999) 325-330
46. Li E., Brown S.L., Stupack D.G., Puente X.S., Cheresh D.A., and Nemerow G.R. Integrin alpha(v)beta1 is an adenovirus coreceptor. J. Virol. 75 11 (2001) 5405-5409
47. Lieber A., He C.Y., Meuse L., Schowalter D., Kirillova I., Winther B., et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71 11 (1997) 8798-8807
48. Liu Q., Zaiss A.K., Colarusso P., Patel K., Haljan G., Wickham T.J., et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther. 14 7 (2003) 627-643
49. Loser P., Hillgenberg M., Arnold W., Both G.W., and Hofmann C. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Ther. 7 17 (2000) 1491-1498
50. Loser P., Huser A., Hillgenberg M., Kumin D., Both G.W., and Hofmann C. Advances in the development of non-human viral DNA-vectors for gene delivery. Curr. Gene Ther. 2 2 (2002) 161-171
51. Loser P., Hofmann C., Both G.W., Uckert W., and Hillgenberg M. Construction, rescue, and characterization of vectors derived from ovine atadenovirus. J. Virol. 77 22 (2003) 11941-11951
52. Louis N., Fender P., Barge A., Kitts P., and Chroboczek J. Cell-binding domain of adenovirus serotype 2 fiber. J. Virol. 68 6 (1994) 4104-4106
53. Maizel Jr. J.V., White D.O., and Scharff M.D. The polypeptides of adenovirus: I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36 1 (1968) 115-125
54. Martin K., Brie A., Saulnier P., Perricaudet M., Yeh P., and Vigne E. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Ther. 8 3 (2003) 485-494
55. Martiniello-Wilks R., Wang X.Y., Voeks D.J., Dane A., Shaw J.M., and Mortensen E. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J. Gene Med. 6 12 (2004) 1343-1357
56. Miller C.R., Buchsbaum D.J., Reynolds P.N., Douglas J.T., Gillespie G.Y., Mayo M.S., et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58 24 (1998) 5738-5748
57. Mizuguchi H., Koizumi N., Hosono T., Ishii-Watabe A., Uchida E., Utoguchi N., et al. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther. 9 12 (2002) 769-776
58. Moullier P., Friedlander G., Calise D., Ronco P., Perricaudet M., and Ferry N. Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int. 45 4 (1994) 1220-1225
59. Nakamura T., Sato K., and Hamada H. Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J. Virol. 77 4 (2003) 2512-2521
60. Nguyen T., Nery J., Joseph S., Rocha C., Carney G., Spindler K., et al. Mouse adenovirus (MAV-1) expression in primary human endothelial cells and generation of a full-length infectious plasmid. Gene Ther. 6 7 (1999) 1291-1297
61. Nicklin S.A., Wu E., Nemerow G.R., and Baker A.H. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol. Ther. 12 3 (2005) 384-393
62. Okegawa T., Li Y., Pong R.C., Bergelson J.M., Zhou J., and Hsieh J.T. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. 60 18 (2000) 5031-5036
63. Ortiz P.A., Hong N.J., Plato C.F., Varela M., and Garvin J.L. An in vivo method for adenovirus-mediated transduction of thick ascending limbs. Kidney Int. 63 3 (2003) 1141-1149
64. Peeters M.J., Patijn G.A., Lieber A., Meuse L., and Kay M.A. Adenovirus-mediated hepatic gene transfer in mice: comparison of intravascular and biliary administration. Hum. Gene Ther. 7 14 (1996) 1693-1699
65. Rasmussen U.B., Benchaibi M., Meyer V., Schlesinger Y., and Schughart K. Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Hum. Gene Ther. 10 16 (1999) 2587-2599
66. Reddy P.S., Idamakanti N., Chen Y., Whale T., Babiuk L.A., Mehtali M., et al. Replication-defective bovine adenovirus type 3 as an expression vector. J. Virol. 73 11 (1999) 9137-9144
67. Reddy P.S., Idamakanti N., Hyun B.H., Tikoo S.K., and Babiuk L.A. Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol. 80 Pt. 3 (1999) 563-570
68. Reynolds P., Dmitriev I., and Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther. 6 7 (1999) 1336-1339
69. Rothel J.S., Boyle D.B., Both G.W., Pye A.D., Waterkeyn J.G., Wood P.R., et al. Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep. Parasite Immunol. 19 5 (1997) 221-227
70. Sakurai F., Mizuguchi H., Yamaguchi T., and Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol. Ther. 8 5 (2003) 813-821
71. Salone B., Martina Y., Piersanti S., Cundari E., Cherubini G., Franqueville L., et al. Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5. J. Virol. 77 24 (2003) 13448-13454
72. Shayakhmetov D.M., Papayannopoulou T., Stamatoyannopoulos G., and Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 74 6 (2000) 2567-2583
73. Shayakhmetov D.M., Li Z.Y., Ni S., and Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78 10 (2004) 5368-5381
74. Shayakhmetov D.M., Gaggar A., Ni S., Li Z.Y., and Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79 12 (2005) 7478-7491
75. Shayakhmetov D.M., Li Z.Y., Ni S., and Lieber A. Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. J. Immunol. 174 11 (2005) 7310-7319
76. Smith T., Idamakanti N., Kylefjord H., Rollence M., King L., Kaloss M., et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol. Ther. 5 6 (2002) 770-779
77. Smith T.A., Idamakanti N., Marshall-Neff J., Rollence M.L., Wright P., Kaloss M., et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. 14 17 (2003) 1595-1604
78. Smith T.A., Idamakanti N., Rollence M.L., Marshall-Neff J., Kim J., Mulgrew K., et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14 8 (2003) 777-787
79. Soudais C., Boutin S., Hong S.S., Chillon M., Danos O., Bergelson J.M., et al. Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J. Virol. 74 22 (2000) 10639-10649
80. Sullivan D.E., Dash S., Du H., Hiramatsu N., Aydin F., Kolls J., et al. Liver-directed gene transfer in non-human primates. Hum. Gene Ther. 8 10 (1997) 1195-1206
81. Takeda S., Takahashi M., Mizukami H., Kobayashi E., Takeuchi K., Hakamata Y., et al. Successful gene transfer using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo. Nephron. Exp. Nephrol. 96 4 (2004) e119-e126
82. Tao N., Gao G.P., Parr M., Johnston J., Baradet T., Wilson J.M., et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3 1 (2001) 28-35
83. Tomko R.P., Xu R., and Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 94 7 (1997) 3352-3356
84. van Raaij M.J., Mitraki A., Lavigne G., and Cusack S. A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein. Nature 401 6756 (1999) 935-938
85. Vigne E., Dedieu J.F., Brie A., Gillardeaux A., Briot D., Benihoud K., et al. Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther. 10 2 (2003) 153-162
86. Voeks D., Martiniello-Wilks R., Madden V., Smith K., Bennetts E., Both G.W., et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 9 12 (2002) 759-768
87. Von Seggern D.J., Huang S., Fleck S.K., Stevenson S.C., and Nemerow G.R. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J. Virol. 74 1 (2000) 354-362
88. Vrati S., Boyle D., Kocherhans R., and Both G.W. Sequence of ovine adenovirus homologs for 100K hexon assembly, 33K, pVIII, and fiber genes: early region E3 is not in the expected location. Virology 209 2 (1995) 400-408
89. Vrati S., Brookes D.E., Strike P., Khatri A., Boyle D.B., and Both G.W. Unique genome arrangement of an ovine adenovirus: identification of new proteins and proteinase cleavage sites. Virology 220 1 (1996) 186-199
90. Wang X., and Bergelson J.M. Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. J. Virol. 73 3 (1999) 2559-2562
91. Wang X.Y., Martiniello-Wilks R., Shaw J.M., Ho T., Coulston N., Cooke-Yarborough C., et al. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther. 11 21 (2004) 1559-1567
92. Wickham T.J., Mathias P., Cheresh D.A., and Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73 2 (1993) 309-319
93. Wood M., Perrotte P., Onishi E., Harper M.E., Dinney C., Pagliaro L., et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 6 4 (1999) 367-372
94. Worgall S., Wolff G., Falck-Pedersen E., and Crystal R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8 1 (1997) 37-44
95. Xia D., Henry L.J., Gerard R.D., and Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 2 12 (1994) 1259-1270
96. Xu Z.Z., and Both G.W. Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5. Virology 248 1 (1998) 156-163
97. Yun C.O., Yoon A.R., Yoo J.Y., Kim H., Kim M., Ha T., et al. Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity. Hum. Gene Ther. 16 2 (2005) 248-261